News

GBR 830 is an antagonist of OX40, a costimulatory receptor expressed on T cells mediating T cell activation and survival. GBR 830 was found to be well tolerated

The 19,000m2 warehouse will have a capacity of around 17,000 pallets and handle all inbound raw materials meant for Novo Nordisk’s production in Denmark. Currently, Novo Nordisk’s facility

This is an effort by Pfizer, which manufactures arthritis pill Celebrex, Prevnar pneumococcal vaccines and the fibromyalgia drug Lyrica, to gain a leading position in the global market

The strategic alliance is aimed at developing new cancer immunotherapies based on Cellectis’ allogeneic chimeric antigen receptor (CAR) platform. MD Anderson Cancer Center’s leukemia and myeloma teams will

The regulatory authority has approved Brilinta tablets at a new dose that could be taken along with aspirin beyond a year of heart attack, reported Reuters. In July

The collaboration will focus on Redx’s existing pan-RAF inhibitor program, which is focused on colorectal cancer, the fourth most common cancer and the second most common cause of

It can be used to treat secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) on hemodialysis therapy. The company said if approved, etelcalcetide will be

The approval is based on four trials of patients receiving emetogenic chemotherapy, including cisplatin, carboplatin and anthracycline/cyclophosphamide-based regimens. Varubi is a selective and competitive antagonist of human substance

DCR-PH1 can be used to treat primary hyperoxaluria type 1 (PH1), which is a rare, inherited disorder of the liver that leads to kidney failure. It features small